Company

Werewolf Therapeutics, Inc.

Headquarters: Cambridge, MA, United States

Employees: 39

CEO: Dr. Daniel J. Hicklin Ph.D.

NASDAQ: HOWL +6.74%

Market Cap

$90.4 Million

USD as of July 1, 2024

Market Cap History

Werewolf Therapeutics, Inc. market capitalization over time

Evolution of Werewolf Therapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Werewolf Therapeutics, Inc.

Detailed Description

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Werewolf Therapeutics, Inc. has the following listings and related stock indices.


Stock: NASDAQ: HOWL wb_incandescent

Details

Headquarters:

1030 Massachusetts Avenue

Suite 210

Cambridge, MA 02138

United States

Phone: 617 952 0555